<DOC>
	<DOCNO>NCT01272089</DOCNO>
	<brief_summary>The purpose study evaluate subject perception Olopatadine 0.2 % , dose once-daily , subject allergic conjunctivitis record adverse event describe subject part post marketing surveillance study .</brief_summary>
	<brief_title>A Study Patient Perception Quality Life Associated With Use Olopatadine 0.2 % Subjects With Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>History ( within past 24 month ) allergic conjunctivitis . Willing avoid contact lens wear study visit , immediately prior study medication installation 10 minute installation study drug . Contact lens wear stable consistent 3 month prior Screening Visit ( Day 1 ) . Other protocoldefined inclusion criterion may apply . Contraindications hypersensitivity use study medication component . Inability unwillingness follow study instruction complete study visit require . Subjects one sight eye correctable ( use ETDRS chart ) 0.6 log MAR good eye Screening Visit . A known history recurrent corneal erosion syndrome ( idiopathic secondary dry eye ) . Ocular trauma within six month prior Visit 1 either eye determine subject history and/or examination . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>